New drug aims to keep leukemia at bay after first treatment

NCT ID NCT07509151

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 5 times

Summary

This Phase 3 trial is testing whether the drug surovatamig can help people with a specific type of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) stay in remission longer after their first round of treatment. About 420 participants will either receive surovatamig as a shot under the skin or be watched without extra treatment. The study focuses on patients whose cancer has a genetic marker called unmutated IGHV, which tends to be more aggressive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Surovatamig (also known as TNB-486, AZD0486) - a drug given as a shot under the skin
What this could lead to: If successful, this could provide a new option to keep CLL/SLL in check longer after initial treatment, potentially delaying relapse.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may cause side effects or not improve outcomes compared to observation alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKAEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WITH UNMUTATED IGHV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia Leukemia, B-Cell lymphoma pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKAEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WITH UNMUTATED IGHV

Contacts and locations

Locations

Research Site
NOT_YET_RECRUITING

Adelaide, 5000, Australia
Research Site
NOT_YET_RECRUITING

Fitzroy, 3065, Australia
Research Site
RECRUITING

Heidelberg, 3084, Australia
Research Site
RECRUITING

Nedlands, 6009, Australia
Research Site
NOT_YET_RECRUITING

Perth, 6847, Australia
Research Site
NOT_YET_RECRUITING

Rockingham, 6168, Australia
Research Site
RECRUITING

Calgary, Alberta, T2N 5G2, Canada
Research Site
SUSPENDED

Vancouver, British Columbia, V5Z 4E6, Canada
Research Site
NOT_YET_RECRUITING

Halifax, Nova Scotia, B3H 2Y9, Canada
Research Site
NOT_YET_RECRUITING

Hamilton, Ontario, L8V 5C2, Canada
Research Site
RECRUITING

Toronto, Ontario, M5G 2L7, Canada
Research Site
SUSPENDED

Montreal, Quebec, H2L 4M1, Canada
Research Site
NOT_YET_RECRUITING

Montreal, Quebec, H3T 1E2, Canada
Research Site
SUSPENDED

Québec, Quebec, G1J 1Z4, Canada
Research Site
RECRUITING

Adapazarı, 54100, Turkey (Türkiye)
Research Site
RECRUITING

Antalya, 07025, Turkey (Türkiye)
Research Site
NOT_YET_RECRUITING

Istanbul, 34098, Turkey (Türkiye)
Research Site
RECRUITING

Istanbul, 34517, Turkey (Türkiye)
Research Site
RECRUITING

Istanbul, 34899, Turkey (Türkiye)
Research Site
RECRUITING

Kocaeli, 41380, Turkey (Türkiye)
Research Site
RECRUITING

Mezitli, 33200, Turkey (Türkiye)
Research Site
RECRUITING

Edinburgh, EH4 2XU, United Kingdom
Research Site
NOT_YET_RECRUITING

Hampshire, SO16 6YD, United Kingdom
Research Site
NOT_YET_RECRUITING

Leeds, LS9 7TF, United Kingdom
Research Site
RECRUITING

London, NW1 2BU, United Kingdom
Research Site
RECRUITING

London, SE5 9RS, United Kingdom
Research Site
RECRUITING

Manchester, M20 4BX, United Kingdom
Research Site
RECRUITING

Nottingham, NG5 1PB, United Kingdom
Research Site
RECRUITING

Oxford, OX3 7LE, United Kingdom
Research Site
NOT_YET_RECRUITING

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.